Comparative Pharmacology
Head-to-head clinical analysis: LOMANATE versus XERMELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMANATE versus XERMELO.
LOMANATE vs XERMELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
Telotristat ethyl is a prodrug that is hydrolyzed to the active metabolite telotristat, an inhibitor of tryptophan hydroxylase (TPH). TPH is the rate-limiting enzyme in the peripheral conversion of tryptophan to serotonin. By inhibiting TPH, telotristat reduces serotonin production in the gut, thereby decreasing gastrointestinal motility and secretion, and reducing diarrhea associated with carcinoid syndrome.
100 mg orally twice daily
250 mg orally three times daily with or without food.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 6-10 hours in patients with carcinoid syndrome, supporting twice-daily dosing. In patients with moderate hepatic impairment, half-life may be prolonged to up to 19 hours.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Primarily excreted via feces (approximately 82% of absorbed dose) with a minor renal component (approximately 12% of absorbed dose as unchanged drug and metabolites).
Category C
Category C
Antidiarrheal
Antidiarrheal